Transfusion Requirements in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria with or without a History of Bone Marrow Disorder Receiving Ravulizumab and Eculizumab: Results from a Phase 3 Non-Inferiority Study Extension

被引：0
|
作者：
Risitano, Antonio
Jang, Jun-Ho
Gyeong-Won, Lee
Wanachiwanawin, Wanchai
Schrezenmeier, Hubert
Yonemura, Yuji
Munir, Talha
Pavani, Rodrigo
Wang, Jimmy
Kulagin, Alexander D.
Kulasekararaj, Austin
De Fontbrune, Flore Sicre
Roth, Alexander
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-140418
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 35 条
  • [1] Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria with or without a history of bone marrow disorder receiving ravulizumab and eculizumab: results from a phase 3 non-inferiority study extension
    Risitano, A.
    Munir, T.
    Jang, J. Ho
    Lee, G-W
    Wanachiwanawin, W.
    Schrezenmeier, H.
    Yonemura, Y.
    Pavani, R.
    Wang, J.
    Kulagin, A.
    Kulasekararaj, A.
    de Fontbrune, F. Sicre
    Roeth, A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 203 - 204
  • [2] Transfusion requirements in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors receiving Ravulizumab or Eculizumab: results from a phase 3 non-inferiority study
    Roeth, A.
    Risitano, A.
    Jang, J. H.
    Lee, G. -W.
    Wanachiwanawin, W.
    Schrezenmeier, H.
    Yonemura, Y.
    Munir, T.
    Pavani, R.
    Aguzzi, R.
    Shafner, L.
    Kulagin, A.
    de Fontbrune, Sicre F.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 97 - 97
  • [3] Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab
    Kulasekararaj, Austin G.
    Hill, Anita
    Rottinghaus, Scott T.
    Langemeijer, Saskia
    Wells, Richard A.
    Gonzalez-Fernandez, F. Ataulfo
    Gaya, Anna
    Lee, Jong-Wook
    Gutierrez, Emilio Ojeda
    Piatek, Caroline I.
    Szer, Jeffrey
    Risitano, Antonio M.
    Nakao, Shinji
    Bachman, Eric
    Shafner, Lori
    Damokosh, Andrew I.
    Ortiz, Stephan
    Roeth, Alexander
    De latour, Regis Peffault
    [J]. BLOOD, 2018, 132
  • [4] One-year efficacy and safety from a phase 3 trial of ravulizumab in adult patients with paroxysmal nocturnal hemoglobinuria receiving prior eculizumab treatment
    Kulasekararaj, A.
    Mitchell, L.
    Hill, A.
    Langemeijer, S.
    Wells, R.
    Gonzalez Fernandez, F. A.
    Gaya, A.
    Gutierrez, O.
    Piatek, C.
    Usuki, K.
    Bosi, A.
    Brodsky, R.
    Ogawa, M.
    Yu, J.
    Ortiz, S.
    Roeth, A.
    Lee, J. W.
    de la Tour, R. Peffault
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 138 - 139
  • [5] One-year efficacy and safety from a phase 3 trial of ravulizumab in adult patients with paroxysmal nocturnal hemoglobinuria receiving prior eculizumab treatment
    Roeth, A.
    Kulasekararaj, A. G.
    Hill, A.
    Langemeijer, S.
    Wells, R.
    Gonzalez Fernandez, F. A.
    Gaya, A.
    Ojeda Gutierrez, E.
    Piatek, C. I.
    Mitchell, L.
    Usuki, K.
    Bosi, A.
    Brodsky, R.
    Ogawa, M.
    Yu, J.
    Ortiz, S.
    Lee, J. W.
    de la Tour, Peffault R.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 173 - 174
  • [6] One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment
    Kulasekararaj, Austin
    Hill, Anita
    Langemeijer, Saskia
    Wells, Richard A.
    Gonzalez-Fernandez, F. Ataulfo
    Gaya, Anna
    Gutierrez, Emilio Ojeda
    Piatek, Caroline I.
    Mitchell, Lindsay D.
    Usuki, Kensuke
    Bosi, Alberto
    Brodsky, Robert A.
    Ogawa, Masayo
    Yu, Ji
    Ortiz, Stephan
    Roth, Alexander
    Lee, Jong-Wook
    de Latour, Regis Peffault
    [J]. BLOOD, 2019, 134
  • [7] A phase 3 study of Ravulizumab (ALXN1210) vs. Eculizumab in adults with paroxysmal nocturnal hemoglobinuria currently treated with Eculizumab: subgroup analysis by transfusion history and demographics
    Risitano, A.
    Roeth, A.
    Hill, A.
    Charbonnier, A.
    Schouten, H. C.
    Khaled, S.
    Gutierrez, E. O.
    Ogawa, M.
    Yu, J.
    Rottinghaus, S.
    Ishiyama, K.
    Kulasekararaj, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 302 - 302
  • [8] Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: results of a 52-week extension from two phase 3 studies
    Hill, A.
    Munir, T.
    Piatek, C.
    de la Tour, R. Peffault
    Lee, L. Wong Lee
    Wells, R.
    Brodsky, R.
    Kim, J. S.
    Nishimura, J.
    Kuriakose, P.
    Pavani, R.
    Liu, P.
    Ortiz, S.
    Schrezenmeier, H.
    Lee, J. W.
    Kulasekararaj, A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 142 - 143
  • [9] Breakthrough hemolysis in adult patients with paroxysmal nocturnal hemoglobinuria treated with Ravulizumab: Results of a 52-week extension from two phase 3 studies
    Schrezenmeier, H.
    Hill, A.
    Piatek, C., I
    de la Tour, Peffault R.
    Lee, Wong Lee L.
    Wells, R.
    Brodsky, R.
    Kim, Seok J.
    Nishimura, J.
    Kuriakose, P.
    Pavani, R.
    Liu, P.
    Ortiz, S.
    Lee, J. W.
    Kulasekararaj, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 177 - 178
  • [10] Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies
    Hill, Anita
    Piatek, Caroline I.
    de Latour, Regis Peffault
    Wong, Lily L. L.
    Wells, Richard A.
    Brodsky, Robert A.
    Kim, Jin Seok
    Nishimura, Junichi
    Kuriakose, Philip
    Pavani, Rodrigo
    Liu, Peng
    Ortiz, Stephan
    Schrezenmeier, Hubert
    Lee, Jong-Wook
    Kulasekararaj, Austin
    [J]. BLOOD, 2019, 134
1234